Article Text

Download PDFPDF
Drug eluting stents: are human and animal studies comparable?
  1. R Virmani1,
  2. F D Kolodgie1,
  3. A Farb1,
  4. A Lafont2
  1. 1Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington DC, USA
  2. 2Hôpital Européen Georges Pompidou, INSERM E00-16, Université, Paris V, France
  1. Correspondence to:
    Dr Renu Virmani, Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, 6825 16th Street NW, Washington DC 20306-6000, USA;


Animal models of stenting probably predict human responses as the stages of healing are remarkably similar. What is characteristically different is the temporal response to healing, which is substantially prolonged in humans. The prevention of restenosis in recent clinical trials of drug eluting stents may represent a near absent or incomplete phase of intimal healing. Continued long term follow up of patients with drug eluting stents for major adverse cardiac events and angiographic restenosis is therefore imperative.

  • stent
  • drug eluting stent
  • coronary artery disease
  • ASPECT, Asian paclitaxel eluting stent clinical trial
  • ELUTES, evaluation of paclitaxel-eluting stent
  • IVUS, intravascular ultrasound
  • MACE, major adverse cardiac event
  • RAVEL, randomised study with the sirolimus eluting velocity balloon expandable stent in treatment of de novo native coronary artery lesions
  • SIRIUS, sirolimus eluting stent

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Linked Articles

  • Miscellanea
    BMJ Publishing Group Ltd and British Cardiovascular Society